NCT02340975 - A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

April 29, 2019

Study Completion Date

April 29, 2019

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL

MEDI4736 + tremelimumab

MEDI4736 will be administered by IV infusion in combination with tremelimumab.

BIOLOGICAL

MEDI4736 + tremelimumab

MEDI4736 will be administered by IV infusion in combination with tremelimumab.

BIOLOGICAL

MEDI4736

MEDI4736 will be administered by IV infusion.

BIOLOGICAL

Tremelimumab

Tremelimumab will be administered by IV infusion.

BIOLOGICAL

MEDI4736+tremelimumab

MEDI4736 will be administered by IV infusion in combination with tremelimumab.

BIOLOGICAL

MEDI4736 + tremelimumab

MEDI4736 will be administered by IV infusion in combination with tremelimumab.

Trial Locations (28)

100

Research Site, Taipei

333

Research Site, Taoyuan District

10032

Research Site, New York

10065

Research Site, New York

10116

Research Site, New York

11217

Research Site, Taipei

13620

Research Site, Seongnam-si

19111

Research Site, Philadelphia

21231

Research Site, Baltimore

29605

Research Site, Greenville

33612

Research Site, Tampa

37203

Research Site, Nashville

44106

Research Site, Cleveland

60637

Research Site, Chicago

77030

Research Site, Houston

90033

Research Site, Los Angeles

90404

Research Site, Santa Monica

97213

Research Site, Portland

119082

Research Site, Singapore

308433

Research Site, Singapore

06520

Research Site, New Haven

H4A 3J1

Research Site, Montreal

216-8511

Research Site, Kawasaki-shi

135-8550

Research Site, Kōtoku

541-8567

Research Site, Osaka

03080

Research Site, Seoul

03722

Research Site, Seoul

06351

Research Site, Seoul